MRI as a method to reveal in-vivo pathology in MS

Journal of Neural Transmission, Supplement

Volumn , Issue 49, 1997, Pages 211-217

  Paty, D W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEGENERATIVE DISEASE; DEMYELINATING DISEASE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; BRAIN; MYELIN SHEATH; PATHOLOGY; PATHOPHYSIOLOGY;

BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MYELIN SHEATH;

EID: 0030612212     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6844-8_22     Document Type: Review

References (19)

1. Arnold DL, Matthews PM, Francis G, Antel J, et al (1991) Proton MR spectroscopic imaging (SI) for metabolic characterization of the brain plaques of demyelinating disease. Neurology 41: 144
2. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36: 76-82
3. Barnes D, McDonald WI, Tofts PS, Johnson G, Landon DN (1986) Magnetic resonance imaging of experimental cerebral oedema. J Neurol Neurosurg Psychiatry 49: 1341-1347
4. Barnes D, McDonald WI, Landon DN, Johnson G (1988) The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. Brain 111: 83-94
5. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI (1991) The longstanding MS lesion. Brain 114: 1271-1280
6. Birken DL, Oldendorf WH (1989) N-acetyl-L-aspartic acid:, a literature review of a compound prominent in H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 13: 23-31
7. Fog T, Linnemann F (1970) The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand [Suppl] 46: 1-175
8. Grossman RI, Lenkinski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA (1992) MR proton spectroscopy in multiple sclerosis. AJNR 13: 1535-1543
9. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF (1993) Correlation between magnetic resonance imaging and lesion development in chronic, active multiple sclerosis. Ann Neurol 34: 661-669
10. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, Rudge P, McDonald WI (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 113: 1477-1489
11. Koopmans RA, Li DKB, Oger JJ, Kastrukoff LF, Jardine C, Costley L, Hall S, Grochowski EW, Paty D W (1989a) Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 26: 248-256
12. Koopmans RA, Li DKB, Oger JJF, Mayo J, Paty DW (1989b) The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology 39: 959-963
13. Koopmans RA, Li DK, Zhu G, Allen PS, Penn A, Paty DW (1993) Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products [letter]. Lancet 341: 631-632
14. Ludwin SK (1988) Remyelination in the central nervous system and peripheral nervous system. Adv Neurol, Funct'l Rec In Neurol Dis 47: 215-254
15. Lumsden CE (1951) Fundamental problems in the pathology of multiple sclerosis and allied demyelinating diseases. BMJ 1: 1035-1043
16. MacKay AL, Whittall KP, Cover KS, Li DK, Paty DW, et al (1991) In vivo T2 relaxation measurements of brain may provide myelin concentration. Society of Magnetic Resonance in Medicine, 10th Annual Meeting, Aug 1991. Book of Abstracts 1: 917
17. Matthews PM, Francis G, Antel J, Arnold DL (1991) Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 41: 1251-1256
18. McDonald WI, Miller DH, Barnes D (1992) The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 18: 319-334
19. Miller DH, Rudge P, Johnson G, Kendall BE, Macmanus DG, Moseley IF, Barnes D, McDonald WI (1988) Brain 111: 927-939